Supernus shares soar on epilepsy drug OK

Shares of Supernus Pharmaceuticals ($SUPN) rocketed up more than 100% yesterday as word spread that the FDA had provided a tentative approval for its extended-release version of the generic epilepsy drug Topamax. The drug--to be marketed as Trokendi XR--is currently only available as a generic immediate-release treatment. Supernus says that only one issue remains: resolving marketing exclusivity on a specific patient population. Supernus shares were up 16% this morning. Story

 

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.